A

Surface Expression: % Positive Cells (MFI)

NK Cells	B7-1 (CD80)	PD1 (CD279)	CD274 (PD-L1)	CD94 (NKG2/KLRD1)	CD158 (KIR2DL1/2/3)
HD NK 1	2.75(146)	0.37(126)	16.7(183)	18(184)	9.20(377)
HD NK 2	1.82(225)	0.39(198)	12.8(256)	27.6(348)	10.5(326)
HD NK 3	0.08(708)	1.01(992)	3.36(763)	0.53(639)	1.48(669)
HD NK 4	1.55(204)	0.20(153)	21.2(252)	12.6(236)	19.6(306)
HaNK	33.4(64.0)	1.34(77.5)	60.6(81.1)	86.9(220)	16.3(77.8)

B

Meningioma Cells	PD1 (CD279)	PD-L1 (CD274)	HLA-ABC	MIC A/B	CEACAM1 (CD66 a/c/e)
IOMM WT	0.67(49.7)	99.9(1841)	100(1763)	4.00(46.7)	4.39(48.7)
IOMM PDL1 KO	0.01(72.8)	6.53(112)	99.6(1371)	0.34(95.2)	0.52(111)

Supplemental Table 1:
Expression of surface inhibitory ligands on NK cells and meningioma tumor cells. (A) Purified healthy NK cells from four donors and HaNK cells were analyzed by flow cytometry. (B) IOMM meningioma and $CD274^{-/-}$ IOMM cells and were analyzed by flow cytometry. Viability was determined for the entire cell populations by live/dead staining as described in materials and methods. For surface expression of indicated molecules, analysis was conduced on gated viable cells. Numbers indicate percentage of positive cells. Numbers in parentheses denote mean fluorescence intensity (MFI). Data shown is representative of experiment repeated 2 times with similar results.